SAREUM HOLDINGS PLC

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  —

  Not reported

• Cash

  +143%

  £1,459,000 → £3,546,000

• Net assets

  +7.7%

  £2,114,000 → £2,277,000

• Employees

  0%

  5 → 5

• Operating profit

  +27.1%

  -£4,634,000 → -£3,380,000

• Profit before tax

  -6.5%

  -£4,602,000 → -£4,903,000

• Wages

  +6.6%

  £530,000 → £565,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. SAREUM HOLDINGS PLC 2004-07-12 → present
2. KEEPFAST PLC 2004-06-07 → 2004-07-12

Accounting basis

UK adopted international accounting standards

Reporting scope

Consolidated group

Auditor

Moore Kingston Smith LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The Directors consider that the cash held at the year-end, together with that received after the year end and projected to be received, will be sufficient for the Company and Group to meet its forecast expenditure for at least one year from the date of signing the financial statements. If there is a shortfall the Directors will implement cost savings to ensure that the cash resources last for this period of time.”

Group structure

1. SAREUM HOLDINGS PLC · parent
   1. Sareum Limited 100% · England and Wales
   2. Sareum Australia Pty Limited 100% · Australia

Significant events

• “We further strengthened our position in oncology in March 2025 by securing the licence for SRA737 on substantially improved economic terms.”
• “Post-period, we expanded our research into new disease areas through a collaboration with Receptor.AI.”
• “In July 2025, Sareum reported positive topline results from the Phase 1 clinical trial conducted in healthy volunteers in Australia.”
• “In October 2025, Sareum discontinued its 16-week GLP preclinical toxicology study for SDC-1801 after unexpected safety findings were observed.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

7

last 12 months

Capital events

13

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.